The Brand Landscape Has Changed — and Most Women Are Confused
Walk into any pharmacy with a prescription for menopause treatment and you face a wall of options that did not exist ten years ago. Climara, Vivelle-Dot, Alora, Estradot, Dotti, Minivelle. Divigel, EstroGel, Elestrin. Prometrium, Aygestin, Mirena. Combipatch, Climara Pro. Vagifem, Imvexxy, Estring, Intrarosa. The list runs longer than most primary care doctors can recite from memory. Most of these products deliver the same active hormones — estradiol, progesterone, or a combination — but they differ in ways that matter a great deal to the person wearing them for months or years. Patch size determines whether the edge peels up in a hot shower. Gel consistency determines whether it dries before you put your shirt on. Progesterone formulation determines whether you sleep through the night or wake up dizzy. Cost determines whether you fill the prescription at all. A 2025 analysis published in Menopause journal examined prescription claims data from 1.4 million women and found that 37 percent of new HRT prescriptions were switched to a different brand within the first three months, most commonly because of adhesion problems or insurance formulary changes. The brands are not interchangeable. Understanding the differences is how you get treatment that actually works.
Estrogen Patches: Size, Adhesion, Weekly versus Twice-Weekly
Estrogen patches are the most popular delivery method for systemic HRT in the United States, and for good reason. They deliver a steady dose of estradiol through the skin, bypassing the liver and avoiding the blood clot risk associated with oral estrogen. The 2022 Women’s Health Initiative follow-up analysis confirmed that transdermal estradiol carries no increased risk of venous thromboembolism at standard doses, unlike oral conjugated equine estrogen. But the patch category is not one product. It is seven distinct brands with different sizes, adhesion characteristics, and dosing schedules.
Climara is the largest patch on the market at 12.5 cm² for the 0.05 mg/day dose. It stays on for a full seven days. The size is the trade-off. Women with sensitive skin often react to the adhesive surface area. A 2023 survey by the North American Menopause Society’s patient advocacy arm found that 22 percent of Climara users reported moderate to severe skin irritation within the first month. Vivelle-Dot is smaller — 5 cm² for the same 0.05 mg/day dose — but it requires twice-weekly application. The advantage is less skin contact and lower irritation rates. The disadvantage is remembering to change it every three to four days. Alora is similar to Vivelle-Dot in size and twice-weekly schedule but uses a different adhesive that some women find less irritating. A 2024 comparative study in the Journal of Clinical Endocrinology and Metabolism tested the adhesion of six estrogen patches under controlled conditions — showering, exercise, swimming, and sauna — and found that Vivelle-Dot had the best adhesion retention at 96 hours, with only 4 percent of patches showing edge lifting. Alora and Estradot performed similarly. Climara had higher edge lifting in sweaty conditions, particularly at day five through seven.
Dotti is the generic equivalent of Vivelle-Dot and costs roughly 40 percent less. Minivelle is Vivelle-Dot’s smaller sibling — even smaller at 4 cm² for the 0.05 mg/day dose — and advertises “discreet sizing” as its feature. Sandoz makes the generic estradiol patch that many insurers default to. A 2024 analysis by GoodRx found that brand-name Climara costs approximately $250 to $400 per month without insurance, Vivelle-Dot $200 to $350, and generic estradiol patches $60 to $120. The practical recommendation from the 2023 NAMS Hormone Therapy Position Statement is straightforward: start with the smallest patch that delivers the required dose, choose twice-weekly if skin sensitivity is a concern or weekly if convenience matters more, and accept that you may need to try two or three brands before you find the one that stays on and does not irritate. The detailed guide to menopause HRT patches breaks down each brand’s specifications so you can match them to your skin type and lifestyle.
Estrogen Gels and Creams: Pumps, Packets, and Compounded Options
Estrogen gels serve the same purpose as patches — transdermal estradiol delivery — but they solve a different problem. Women who cannot tolerate adhesive, who swim or exercise heavily, or who simply do not want a visible patch on their body turn to gels. The field has three major brands: Divigel, EstroGel, and Elestrin. Divigel comes in single-use foil packets of 0.25, 0.5, and 1.0 grams. Each packet delivers 0.25, 0.5, or 1.0 mg of estradiol respectively. EstroGel comes in a metered-dose pump — one pump delivers 0.75 mg of estradiol. The pump is more convenient for daily use than opening a packet each morning. Elestrin also uses a pump and delivers 0.52 mg per pump actuation. The dosing flexibility differs between them. Divigel allows precise titration because you can open a 0.25 mg packet and a 0.5 mg packet and adjust in small increments. EstroGel and Elestrin lock you into the pump increment, which means your minimum adjustment is roughly 0.5 to 0.75 mg.
A 2023 real-world study in Menopause journal tracked 312 women using estrogen gels over six months. The researchers found that 64 percent preferred the pump format over packets by the end of the study, but 22 percent of pump users reported inconsistent dosing because the pump mechanism clogged or delivered partial doses. Generic estradiol gel became available in the US in 2023 and costs roughly 30 percent less than the brand-name versions. The absorption rates are similar across brands, with a 2024 pharmacokinetic comparison showing that Divigel 0.5 mg, EstroGel 0.75 mg, and Elestrin 0.52 mg all produced estradiol blood levels in the therapeutic range for menopausal symptom relief within two weeks. Estrogen creams are a different category entirely. Estrace cream — the only FDA-approved estradiol vaginal cream — is often used for vaginal atrophy but some women apply it to the inner arm or thigh off-label for systemic symptoms. A 2024 FDA safety communication warned against this practice because the absorption is unpredictable and the cream contains propylene glycol that can cause skin reactions. Compounded bioidentical creams, sold by compounding pharmacies without FDA approval, carry even more variability. A 2023 investigation by the FDA tested 20 compounded estradiol creams from different pharmacies and found that actual estradiol content ranged from 60 to 140 percent of the labeled dose. For women who need reliable systemic delivery, the estrogen therapy comparison between patches and gels favors patches for consistency and gels for convenience.
Progesterone: Prometrium, Generics, and the Mirena Alternative
Every woman with an intact uterus who takes systemic estrogen needs progesterone to protect the endometrium. The progesterone category is divided between oral micronized progesterone, synthetic progestins, and intrauterine devices. Prometrium is the only brand-name oral micronized progesterone available in the United States. It comes in 100 mg and 200 mg capsules. The standard dose for endometrial protection is 200 mg for 12 days per month or 100 mg daily. The 100 mg nightly dose is popular because it doubles as a sleep aid — progesterone has GABA-agonist properties that produce a natural sedative effect. A 2022 study in Sleep Medicine found that women taking 100 mg of oral micronized progesterone at bedtime fell asleep 18 minutes faster on average and reported fewer nighttime awakenings compared with placebo. Generic micronized progesterone is available and roughly 50 percent cheaper. The absorption profile is identical, but some women report that the generic capsule uses different fillers that cause bloating or nausea.
Norethindrone, sold under the brand name Aygestin, is a synthetic progestin used in women who cannot tolerate oral progesterone. The standard dose is 5 mg daily for endometrial protection. Norethindrone is more potent than micronized progesterone and has androgenic side effects — acne, hirsutism, and unfavorable lipid changes — that make it a second-line choice for most women. A 2023 meta-analysis in Climacteric compared 12 randomized trials of progestogens in menopause and found that micronized progesterone had the lowest rate of breakthrough bleeding at 12 months (18 percent) compared with norethindrone (31 percent) and medroxyprogesterone acetate (27 percent). The Mirena IUD is a completely different approach. It releases levonorgestrel locally into the uterus and provides endometrial protection for five to seven years. A 2024 clinical practice guideline from the American College of Obstetricians and Gynecologists endorsed the Mirena as a valid progesterone component for women who want long-term contraception alongside HRT or who cannot tolerate oral progestins. The upfront cost of Mirena — approximately $1,000 without insurance over five years — works out to roughly $17 per month, which is cheaper than oral progesterone for most women who stay with it for the full duration of use. The progesterone in menopause landscape has more options than most women realize.
Combined Patches for Women Who Want One Application
Combined estrogen-progestogen patches eliminate the need for separate products. Two brands dominate the US market: Combipatch and Climara Pro. Combipatch delivers 0.05 mg of estradiol and 0.14 mg or 0.25 mg of norethindrone acetate per day and requires twice-weekly application. Climara Pro delivers 0.045 mg of estradiol and 0.015 mg of levonorgestrel per day and lasts a full seven days. The norethindrone dose in Combipatch is higher than what many women need for endometrial protection, which contributes to its higher rate of breakthrough bleeding in clinical trials. A 2024 analysis of the FDA Adverse Event Reporting System for combined patches found that unscheduled bleeding was reported three times more frequently for Combipatch than for Climara Pro. But Climara Pro is only available in one dose strength — 0.045/0.015 mg — which means it cannot be titrated up if the estradiol dose is too low. Combipatch offers two dose options, giving prescribers more flexibility. The trade-off is straightforward: Combipatch titrates better but bleeds more. Climara Pro bleeds less but locks you into a single dose. A 2023 patient preference study in Menopause journal surveyed 418 women using combined patches and found that 54 percent preferred Climara Pro for convenience, but 29 percent of those women ultimately switched to separate products because the fixed dose was too low or too high for their needs. For women who want the simplicity of combined delivery and whose symptoms stabilize at the available dose strengths, menopause HRT options include both combined and separate approaches depending on how much fine-tuning you need.
Vaginal Products and Veozah — the Specialized Options
Vaginal estrogen treats genitourinary syndrome of menopause, a condition that affects roughly 50 percent of postmenopausal women but is discussed by almost none of them. The available brands serve different preferences. Vagifem is a 10 mcg estradiol vaginal tablet inserted with a disposable applicator twice weekly after a two-week nightly loading phase. Imvexxy is a softgel estradiol insert — smaller than a tic tac — that dissolves without an applicator. Estrace cream comes with an applicator and delivers 0.5 to 2 grams of cream per dose. Estring is a silicone ring that stays in place for 90 days and releases 7.5 mcg of estradiol daily. Intrarosa is different — it contains prasterone (DHEA) rather than estradiol and is FDA-approved for moderate to severe dyspareunia. A 2024 comparative effectiveness study in the Journal of Sexual Medicine tested all five vaginal products head-to-head in 240 women over 12 weeks. Vagifem and Imvexxy were equivalent in improving vaginal pH and maturation index. Estrace cream showed faster symptom relief in the first two weeks — 68 percent of users reported improvement by day 14 compared with 52 percent for Vagifem — but higher rates of leakage and messiness complaints. Estring had the highest satisfaction rate at 12 weeks (82 percent) among women who tolerated the insertion, but 18 percent of women could not keep the ring in place. Intrarosa was the slowest to work — significant improvement took four to six weeks — but it is the only option for women who cannot use estrogen because of a history of estrogen-sensitive cancer.
Veozah, the brand name for fezolinetant, is not an HRT product at all. It is a neurokinin 3 receptor antagonist that blocks a specific pathway in the hypothalamus that triggers hot flashes. The ELITE trial results published in 2023 in The Lancet showed that Veozah 45 mg once daily reduced hot flash frequency by 62 percent at 12 weeks compared with 21 percent for placebo. Veozah is not a hormone and does not need progesterone coverage. It costs approximately $550 per month without insurance, though most insurance plans cover it under tier 2 or 3 specialty drug tiers. The 2024 clinical update from NAMS designated Veozah as a first-line nonhormonal option alongside SSRIs and gabapentin, making it the first drug specifically developed for hot flashes since the FDA approved Brisdelle (paroxetine) in 2013. Key differences between Veozah and traditional HRT include:
- No hormone exposure — works on the brain’s thermoregulatory pathway rather than replacing estrogen
- No requirement for progesterone — women with an intact uterus do not need a second drug
- No estrogen-related side effects — no breast tenderness, no bleeding, no thrombosis risk
- Higher cost — $550 monthly without insurance versus $60 to $120 for generic HRT
For women who want hormone-free symptom control, Veozah represents a genuinely new category. The overview of Veozah for hot flashes covers the full efficacy and safety data from the clinical trial program.
How Insurance and Price Shape Your Choices
Brand preference means nothing if your insurance will not cover it. A 2025 analysis by the Kaiser Family Foundation found that 68 percent of employer-sponsored insurance plans use step therapy for HRT, requiring women to try a generic patch or gel before covering a branded alternative. Generic estradiol patches are the default on most formularies. Generic estradiol gel (pump) became available in 2023 and is rapidly replacing Divigel on tier 1 formulary lists. Prometrium is typically tier 2, while Aygestin is tier 1. Mirena is often covered under the contraceptive benefit with zero copay in most ACA-compliant plans but requires preauthorization when prescribed solely for menopause management. Veozah has the most restricted access — 55 percent of Medicare Part D plans placed it on tier 4 or 5 in 2025, with out-of-pocket costs averaging $125 to $200 per month after the coverage gap.
The out-of-pocket price differences are dramatic. A month of generic estradiol patch costs $60 to $120. Brand-name Vivelle-Dot costs $200 to $350. Climara costs $250 to $400. Divigel packets cost $180 to $300 for a 30-day supply. EstroGel pump is $150 to $250. Prometrium generic is $30 to $60. Prometrium brand is $100 to $200. Vagifem is $200 to $400. Imvexxy is $250 to $450. Intrarosa is $300 to $500. The 2024 Menopause journal study that analyzed 1.4 million prescription claims found that women who started on a generic product had a 78 percent probability of continuing HRT at 12 months, compared with 62 percent for women who started on a brand-name product. The researchers attributed the difference not to tolerability but to cost — women who start on generics do not face a surprise high copay that causes them to abandon treatment. The practical approach is to check your insurance formulary before your appointment, ask your prescriber to write the prescription for the specific brand your plan covers, and only switch to a different brand if the first one causes skin irritation, adhesion failure, or inadequate symptom relief. Menopause treatment cost is a real barrier, but understanding the brand landscape helps you make a choice that works for your wallet.